Title: Initial Development and Validation of a Disease-Specific Resilience Measure for
Inflammatory Bowel Disease: The RISE-IBD Instrument
Version: 0 Date: 20 Mar 2025
Reviewer:  Charles N. Bernstein
Reviewer's report:
The premise of this study is a very important one, that is to validate a resilience scale specific
for IBD patients. It is always important when possible to develop psychometric scale specific
for a disease process rather than using generic ones. The study is very well done.
Participants in the development  (qualitative) phase had a disease duration of ~10 years.
Hence, they may have developed some resilience to their disease even if their personalities
are not necessarily highly resilient. Can the authors comment on how this may have skewed
development of the measure as opposed to having a mix of newly diagnosed patients where
resilience toward in the presence of a new chronic disease may be less.  I have the same
question for the validation phase considering the cohort also had a mean disease duration of
~10 years. Do the authors think a newly diagnosed cohort (at a time where a resilience scale
should be administered, to be most helpful to guide psychogastroenterology clinicians) might
have different psychometrics of the RISE-IBD compared to the generic resilience measures or
depression (?stronger negative correlation)
The authors explore differences in resilience scores among anti TNF users vs non users or by race
or employment status or even specific symptoms like pain.  What about something obvious like
age?  Might older persons be more resilient than younger persons  Were there enough participants
younger than say 30 to compare to older persons?
The higher resilience in anti TNF users might simply reflect disease remission as opposed to a
drug effect. This warrants a comment.
Title: Initial Development and Validation of a Disease-Specific Resilience Measure for
Inflammatory Bowel Disease: The RISE-IBD Instrument
Version: 0 Date: 20 Mar 2025
Reviewer:  Charles N. Bernstein
Reviewer's report:
The premise of this study is a very important one, that is to validate a resilience scale specific
for IBD patients. It is always important when possible to develop psychometric scale specific
for a disease process rather than using generic ones. The study is very well done.
Participants in the development  (qualitative) phase had a disease duration of ~10 years.
Hence, they may have developed some resilience to their disease even if their personalities
are not necessarily highly resilient. Can the authors comment on how this may have skewed
development of the measure as opposed to having a mix of newly diagnosed patients where
resilience toward in the presence of a new chronic disease may be less.  I have the same
question for the validation phase considering the cohort also had a mean disease duration of
~10 years. Do the authors think a newly diagnosed cohort (at a time where a resilience scale
should be administered, to be most helpful to guide psychogastroenterology clinicians) might
have different psychometrics of the RISE-IBD compared to the generic resilience measures or
depression (?stronger negative correlation)
The authors explore differences in resilience scores among anti TNF users vs non users or by race
or employment status or even specific symptoms like pain.  What about something obvious like
age?  Might older persons be more resilient than younger persons  Were there enough participants
younger than say 30 to compare to older persons?
The higher resilience in anti TNF users might simply reflect disease remission as opposed to a
drug effect. This warrants a comment.
Please review this paper.
user
Title: Initial Development and Validation of a Disease-Specific Resilience Measure for
Inflammatory Bowel Disease: The RISE-IBD Instrument
Version: 0 Date: 20 Mar 2025
Reviewer:  Charles N. Bernstein
Reviewer's report:
The premise of this study is a very important one, that is to validate a resilience scale specific
for IBD patients. It is always important when possible to develop psychometric scale specific
for a disease process rather than using generic ones. The study is very well done.
Participants in the development  (qualitative) phase had a disease duration of ~10 years.
Hence, they may have developed some resilience to their disease even if their personalities
are not necessarily highly resilient. Can the authors comment on how this may have skewed
development of the measure as opposed to having a mix of newly diagnosed patients where
resilience toward in the presence of a new chronic disease may be less.  I have the same
question for the validation phase considering the cohort also had a mean disease duration of
~10 years. Do the authors think a newly diagnosed cohort (at a time where a resilience scale
should be administered, to be most helpful to guide psychogastroenterology clinicians) might
have different psychometrics of the RISE-IBD compared to the generic resilience measures or
depression (?stronger negative correlation)
The authors explore differences in resilience scores among anti TNF users vs non users or by race
or employment status or even specific symptoms like pain.  What about something obvious like
age?  Might older persons be more resilient than younger persons  Were there enough participants
younger than say 30 to compare to older persons?
The higher resilience in anti TNF users might simply reflect disease remission as opposed to a
drug effect. This warrants a comment.
assistant